The incidence of metabolic dysfunction-associated steatohepatitis (MASH) is growing rapidly. Patients with or at risk for MASH are underdiagnosed, and thus they may not be benefiting from newly approved liver-directed therapies that can alter the disease course. In this case-based symposium, compete against your colleagues as you trek across desert landscapes in search of critical information about noninvasive testing for MASH, risk stratification, treatment selection and monitoring, and other important topics. The race is on to explore MASH treatments and search for "best practices" that you can implement in your own MASH care pathways. Join us and test your knowledge in this Dash for Mash!